Antitumor Mechanisms of Molecules Secreted by Trypanosoma cruzi in Colon and Breast Cancer: A Review

  • Authors: Sadr S.1, Ghiassi S.2, Lotfalizadeh N.3, Simab P.4, Hajjafari A.5, Borji H.6
  • Affiliations:
    1. Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhadd
    2. Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad
    3. Department of Clinical Sciences, Faculty of Veterinary Medicine,, Ferdowsi University of Mashhad
    4. Department of Pathobiology, Faculty of Veterinary Medicine, Sanandaj Branch, Islamic Azad University
    5. Department of Pathobiology, Faculty of Veterinary Medicine,, Islamic Azad University, Science and Research Branch
    6. Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad
  • Issue: Vol 23, No 15 (2023)
  • Pages: 1710-1721
  • Section: Oncology
  • URL: https://hum-ecol.ru/1871-5206/article/view/694344
  • DOI: https://doi.org/10.2174/1871520623666230529141544
  • ID: 694344

Cite item

Full Text

Abstract

Background: Molecules secreted by Trypanosoma cruzi (T. cruzi) have beneficial effects on the immune system and can fight against cancer by inhibiting the growth of tumor cells, preventing angiogenesis, and promoting immune activation.

Objective: This study aimed to investigate the effects of molecules secreted by Trypanosoma cruzi on the growth of colon and breast cancer cells, to understand the underlying mechanisms of action.

Results: Calreticulin from T. cruzi, a 45 kDa protein, participates in essential changes in the tumor microenvironment by triggering an adaptive immune response, exerting an antiangiogenic effect, and inhibiting cell growth. On the other hand, a 21 kDa protein (P21) secreted at all stages of the parasite's life cycle can inhibit cell invasion and migration. Mucins, such as Tn, sialyl-Tn, and TF, are present both in tumor cells and on the surface of T. cruzi and are characterized as common antigenic determinants, inducing a cross-immune response. In addition, molecules secreted by the parasite are used recombinantly in immunotherapy against cancer for their ability to generate a reliable and long-lasting immune response.

Conclusion: By elucidating the antitumor mechanisms of the molecules secreted by T. cruzi, this study provides valuable insights for developing novel therapeutic strategies to combat colon and breast cancer.

About the authors

Soheil Sadr

Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhadd

Email: info@benthamscience.net

Shakila Ghiassi

Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad

Email: info@benthamscience.net

Narges Lotfalizadeh

Department of Clinical Sciences, Faculty of Veterinary Medicine,, Ferdowsi University of Mashhad

Email: info@benthamscience.net

Pouria Simab

Department of Pathobiology, Faculty of Veterinary Medicine, Sanandaj Branch, Islamic Azad University

Email: info@benthamscience.net

Ashkan Hajjafari

Department of Pathobiology, Faculty of Veterinary Medicine,, Islamic Azad University, Science and Research Branch

Email: info@benthamscience.net

Hassan Borji

Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad

Author for correspondence.
Email: info@benthamscience.net

References

  1. Ailioaie, L.M.; Ailioaie, C.; Litscher, G. Latest innovations and nanotechnologies with curcumin as a nature-inspired photosensitizer applied in the photodynamic therapy of cancer. Pharmaceutics, 2021, 13(10), 1562. doi: 10.3390/pharmaceutics13101562 PMID: 34683855
  2. Najafi, M.; Majidpoor, J.; Toolee, H.; Mortezaee, K. The current knowledge concerning solid cancer and therapy. J. Biochem. Mol. Toxicol., 2021, 35(11), e22900. doi: 10.1002/jbt.22900 PMID: 34462987
  3. Araghi, M.; Soerjomataram, I.; Jenkins, M.; Brierley, J.; Morris, E.; Bray, F.; Arnold, M. Global trends in colorectal cancer mortality: projections to the year 2035. Int. J. Cancer, 2019, 144(12), 2992-3000. doi: 10.1002/ijc.32055 PMID: 30536395
  4. Joseph, D.A.; King, J.B.; Dowling, N.F.; Thomas, C.C.; Richardson, L.C. Vital signs: Colorectal cancer screening test use—United States, 2018. MMWR Morb. Mortal. Wkly. Rep., 2020, 69(10), 253-259. doi: 10.15585/mmwr.mm6910a1 PMID: 32163384
  5. Hussain, A.M.A.; Lafta, R.K. Cancer trends in Iraq 2000–2016. Oman Med. J., 2021, 36(1), e219. doi: 10.5001/omj.2021.18 PMID: 33552559
  6. Kow, A.W.C. Hepatic metastasis from colorectal cancer. J. Gastrointest. Oncol., 2019, 10(6), 1274-1298. doi: 10.21037/jgo.2019.08.06 PMID: 31949948
  7. Kaushik, I.; Ramachandran, S.; Prasad, S.; Srivastava, S.K. Drug rechanneling: A novel paradigm for cancer treatment. Semin. Cancer Biol., 2021, 68, 279-290. doi: 10.1016/j.semcancer.2020.03.011 PMID: 32437876
  8. Gao, Q.; Feng, J.; Liu, W.; Wen, C.; Wu, Y.; Liao, Q.; Zou, L.; Sui, X.; Xie, T.; Zhang, J.; Hu, Y. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv. Drug Deliv. Rev., 2022, 188, 114445. doi: 10.1016/j.addr.2022.114445 PMID: 35820601
  9. Stewart, C.; Ralyea, C.; Lockwood, S. Ovarian cancer: An integrated review. Semin. Oncol. Nurs., 2019, 35(2), 151-156. doi: 10.1016/j.soncn.2019.02.001 PMID: 30867104
  10. Liang, J.L.; Luo, G.F.; Chen, W.H.; Zhang, X.Z. Recent advances in engineered materials for immunotherapy‐involved combination cancer therapy. Adv. Mater., 2021, 33(31), 2007630. doi: 10.1002/adma.202007630 PMID: 34050564
  11. Saxena, M.; van der Burg, S.H.; Melief, C.J.M.; Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer, 2021, 21(6), 360-378. doi: 10.1038/s41568-021-00346-0 PMID: 33907315
  12. Hollingsworth, R.E.; Jansen, K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines, 2019, 4(1), 7. doi: 10.1038/s41541-019-0103-y PMID: 30774998
  13. Eissa, M.M.; Ismail, C.A.; El-Azzouni, M.Z.; Ghazy, A.A.; Hadi, M.A. Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer. Invest. New Drugs, 2019, 37(1), 47-56. doi: 10.1007/s10637-018-0609-6 PMID: 29808307
  14. Darani, H.Y.; Yousefi, M. Parasites and cancers: Parasite antigens as possible targets for cancer immunotherapy. Future Oncol., 2012, 8(12), 1529-1535. doi: 10.2217/fon.12.155 PMID: 23231515
  15. Guan, W.; Zhang, X.; Wang, X.; Lu, S.; Yin, J.; Zhang, J. Employing parasite against cancer: A lesson from the canine tapeworm Echinococcus granulocus. Front. Pharmacol., 2019, 10, 1137. doi: 10.3389/fphar.2019.01137 PMID: 31607934
  16. Yousofi Darani, H.; Daneshpour, S.; Kefayat, A.H.; Mofid, M.R.; Rostami Rad, S. Effect of hydatid cyst fluid antigens on induction of apoptosis on breast cancer cells. Adv. Biomed. Res., 2019, 8(1), 27. doi: 10.4103/abr.abr_220_18 PMID: 31123670
  17. Zininga, T.; Ramatsui, L.; Shonhai, A. Heat shock proteins as immunomodulants. Molecules, 2018, 23(11), 2846. doi: 10.3390/molecules23112846 PMID: 30388847
  18. Huang, J.; Yang, B.; Peng, Y.; Huang, J.; Wong, S.H.D.; Bian, L.; Zhu, K.; Shuai, X.; Han, S. Nanomedicine‐boosting tumor immunogenicity for enhanced immunotherapy. Adv. Funct. Mater., 2021, 31(21), 2011171. doi: 10.1002/adfm.202011171
  19. Junqueira, C.; Santos, L.I.; Galvão-Filho, B.; Teixeira, S.M.; Rodrigues, F.G.; DaRocha, W.D.; Chiari, E.; Jungbluth, A.A.; Ritter, G.; Gnjatic, S.; Old, L.J.; Gazzinelli, R.T. Trypanosoma cruzi as an effective cancer antigen delivery vector. Proc. Natl. Acad. Sci. USA, 2011, 108(49), 19695-19700. doi: 10.1073/pnas.1110030108 PMID: 22114198
  20. Chen, L.; He, Z.; Qin, L.; Li, Q.; Shi, X.; Zhao, S.; Chen, L.; Zhong, N.; Chen, X. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One, 2011, 6(9), e24407. doi: 10.1371/journal.pone.0024407 PMID: 21931708
  21. Berriel, E.; Russo, S.; Monin, L.; Festari, M.F.; Berois, N.; Fernández, G.; Freire, T.; Osinaga, E. Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. Sc. World J. , 2013, 2013, 1-7. doi: 10.1155/2013/230176 PMID: 24023528
  22. Ubillos, L.; Freire, T.; Berriel, E.; Chiribao, M.L.; Chiale, C.; Festari, M.F.; Medeiros, A.; Mazal, D.; Rondán, M.; Bollati-Fogolín, M.; Rabinovich, G.A.; Robello, C.; Osinaga, E. Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Int. J. Cancer, 2016, 138(7), 1719-1731. doi: 10.1002/ijc.29910 PMID: 26519949
  23. Baird, J.R.; Fox, B.A.; Sanders, K.L.; Lizotte, P.H.; Cubillos-Ruiz, J.R.; Scarlett, U.K.; Rutkowski, M.R.; Conejo-Garcia, J.R.; Fiering, S.; Bzik, D.J. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res., 2013, 73(13), 3842-3851. doi: 10.1158/0008-5472.CAN-12-1974 PMID: 23704211
  24. Lidani, K.C.F.; Andrade, F.A.; Bavia, L.; Damasceno, F.S.; Beltrame, M.H.; Messias-Reason, I.J.; Sandri, T.L. Chagas disease: From discovery to a worldwide health problem. Front. Public Health, 2019, 7, 166. doi: 10.3389/fpubh.2019.00166 PMID: 31312626
  25. Echavarría, N.G.; Echeverría, L.E.; Stewart, M.; Gallego, C.; Saldarriaga, C. Chagas disease: Chronic chagas cardiomyopathy. Curr. Probl. Cardiol., 2021, 46(3), 100507. doi: 10.1016/j.cpcardiol.2019.100507 PMID: 31983471
  26. Pérez-Molina, J.A.; Molina, I. Chagas disease. Lancet, 2018, 391(10115), 82-94. doi: 10.1016/S0140-6736(17)31612-4 PMID: 28673423
  27. Martín-Escolano, J.; Marín, C.; Rosales, M.J.; Tsaousis, A.D.; Medina-Carmona, E.; Martín-Escolano, R. An updated view of the Trypanosoma cruzi life cycle: Intervention points for an effective treatment. ACS Infect. Dis., 2022, 8(6), 1107-1115. doi: 10.1021/acsinfecdis.2c00123 PMID: 35652513
  28. Bivona, A.E.; Alberti, A.S.; Cerny, N.; Trinitario, S.N.; Malchiodi, E.L. Chagas disease vaccine design: The search for an efficient Trypanosoma cruzi immune-mediated control. Biochim. Biophys. Acta Mol. Basis Dis., 2020, 1866(5), 165658. doi: 10.1016/j.bbadis.2019.165658 PMID: 31904415
  29. Villanueva-Lizama, L.E.; Cruz-Chan, J.V.; Versteeg, L.; Teh-Poot, C.F.; Hoffman, K.; Kendricks, A.; Keegan, B.; Pollet, J.; Gusovsky, F.; Hotez, P.J.; Bottazzi, M.E.; Jones, K.M. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol., 2020, 42(10), e12769. doi: 10.1111/pim.12769 PMID: 32592180
  30. Acosta, R.E.V.; Araujo, F.C.L.; Fiocca, V.F.; Montes, C.L.; Gruppi, A. Understanding CD8+ T cell immunity to Trypanosoma cruzi and how to improve it. Trends Parasitol., 2019, 35(11), 899-917. doi: 10.1016/j.pt.2019.08.006 PMID: 31607632
  31. Ramírez-Toloza, G.; Sosoniuk-Roche, E.; Valck, C.; Aguilar-Guzmán, L.; Ferreira, V.P.; Ferreira, A. Trypanosoma cruzi calreticulin: Immune evasion, infectivity, and tumorigenesis. Trends Parasitol., 2020, 36(4), 368-381. doi: 10.1016/j.pt.2020.01.007 PMID: 32191851
  32. Borges, B.C.; Uehara, I.A.; dos Santos, M.A.; Martins, F.A.; de Souza, F.C.; Junior, Á.F.; da Luz, F.A.C.; da Costa, M.S.; Notário, A.F.O.; Lopes, D.S.; Teixeira, S.C.; Teixeira, T.L.; de Castilhos, P.; da Silva, C.V.; Silva, M.J.B. The recombinant protein based on Trypanosoma cruzi P21 interacts with CXCR4 receptor and abrogates the invasive phenotype of human breast cancer cells. Front. Cell Dev. Biol., 2020, 8, 569729. doi: 10.3389/fcell.2020.569729 PMID: 33195200
  33. Garcia, S.B.; Aranha, A.L.; Garcia, F.R.B.; Basile, F.V.; Pinto, A.P.M.; Oliveira, E.C.; Zucoloto, S. A retrospective study of histopathological findings in 894 cases of megacolon: What is the relationship between megacolon and colonic cancer? Rev. Inst. Med. Trop. São Paulo, 2003, 45(2), 91-93. doi: 10.1590/S0036-46652003000200007 PMID: 12754574
  34. Menna-Barreto, R.F.S.; Salomão, K.; Dantas, A.P.; Santa-Rita, R.M.; Soares, M.J.; Barbosa, H.S.; de Castro, S.L. Different cell death pathways induced by drugs in Trypanosoma cruzi: An ultrastructural study. Micron, 2009, 40(2), 157-168. doi: 10.1016/j.micron.2008.08.003 PMID: 18849169
  35. de Castro Andreassa, E.; Santos, M.D.M.; Wassmandorf, R.; Wippel, H.H.; Carvalho, P.C.; Fischer, J.S.G.; Souza, T.A.C.B. Proteomic changes in Trypanosoma cruzi epimastigotes treated with the proapoptotic compound PAC-1. Biochim. Biophys. Acta. Proteins Proteomics, 2021, 1869(2), 140582. doi: 10.1016/j.bbapap.2020.140582 PMID: 33285319
  36. Atayde, V.D.; Jasiulionis, M.G.; Cortez, M.; Yoshida, N. A recombinant protein based on Trypanosoma cruzi surface molecule gp82 induces apoptotic cell death in melanoma cells. Melanoma Res., 2008, 18(3), 172-183. doi: 10.1097/CMR.0b013e3282feeaab PMID: 18477891
  37. Cardoso, M.S.; Reis-Cunha, J.L.; Bartholomeu, D.C. Evasion of the immune response by Trypanosoma cruzi during acute infection. Front. Immunol., 2016, 6, 659. doi: 10.3389/fimmu.2015.00659 PMID: 26834737
  38. Bunkofske, M.E.; Perumal, N.; White, B.; Strauch, E.M.; Tarleton, R. Epitopes in the glycosylphosphatidylinositol attachment signal peptide of Trypanosoma cruzi mucin proteins generate robust but delayed and nonprotective CD8+ T cell responses. J. Immunol., 2023, 210(4), 420-430. doi: 10.4049/jimmunol.2200723 PMID: 36603035
  39. Taylor, M.C.; Ward, A.; Olmo, F.; Jayawardhana, S.; Francisco, A.F.; Lewis, M.D.; Kelly, J.M. Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection. PLoS Negl. Trop. Dis., 2020, 14(3), e0008007. doi: 10.1371/journal.pntd.0008007 PMID: 32196491
  40. Abras, A.; Ballart, C.; Fernández-Arévalo, A.; Pinazo, M.J.; Gascón, J.; Muñoz, C.; Gállego, M. Worldwide control and management of Chagas disease in a new era of globalization: A close look at congenital Trypanosoma cruzi infection. Clin. Microbiol. Rev., 2022, 35(2), e00152-e21. doi: 10.1128/cmr.00152-21 PMID: 35239422
  41. Carlier, Y.; Altcheh, J.; Angheben, A.; Freilij, H.; Luquetti, A.O.; Schijman, A.G.; Segovia, M.; Wagner, N.; Albajar Vinas, P. Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women. PLoS Negl. Trop. Dis., 2019, 13(10), e0007694. doi: 10.1371/journal.pntd.0007694 PMID: 31647811
  42. Guarner, J. Chagas disease as example of a reemerging parasite. Semin. Diagn. Pathol., 2019, 36(3), 164-169. doi: 10.1053/j.semdp.2019.04.008 PMID: 31006555
  43. Rios, L.; Campos, E.E.; Menon, R.; Zago, M.P.; Garg, N.J. Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease. Biochim. Biophys. Acta Mol. Basis Dis., 2020, 1866(3), 165591. doi: 10.1016/j.bbadis.2019.165591 PMID: 31678160
  44. Chatelain, E.; Konar, N. Translational challenges of animal models in Chagas disease drug development: A review. Drug Des. Devel. Ther., 2015, 9, 4807-4823. doi: 10.2147/DDDT.S90208 PMID: 26316715
  45. Pino-Marín, A.; Medina-Rincón, G.J.; Gallo-Bernal, S.; Duran-Crane, A.; Arango Duque, Á.I.; Rodríguez, M.J.; Medina-Mur, R.; Manrique, F.T.; Forero, J.F.; Medina, H.M. Chagas cardiomyopathy: From Romaña sign to heart failure and sudden cardiac death. Pathogens, 2021, 10(5), 505. doi: 10.3390/pathogens10050505 PMID: 33922366
  46. Zuma, A.A.; Dos Santos, B.E.; de Souza, W. Basic biology of Trypanosoma cruzi. Curr. Pharm. Des., 2021, 27(14), 1671-1732. doi: 10.2174/18734286MTEyDMDQ2z PMID: 33272165
  47. Bonfim-Melo, A.; Ferreira, E.R.; Florentino, P.T.V.; Mortara, R.A. Amastigote synapse: The tricks of Trypanosoma cruzi extracellular amastigotes. Front. Microbiol., 2018, 9, 1341. doi: 10.3389/fmicb.2018.01341 PMID: 30013522
  48. Araujo, F.C.L.; Tosello, B.J.; Rodriguez, C.; Canale, F.P.; Fiocca, V.F.; Boccardo, S.; Beccaria, C.G.; Adoue, V.; Joffre, O.; Gruppi, A.; Montes, C.L.; Acosta, R.E.V. Limited Foxp3+ regulatory T cells response during acute Trypanosoma cruzi infection is required to allow the emergence of robust parasite-specific CD8+ T cell immunity. Front. Immunol., 2018, 9, 2555. doi: 10.3389/fimmu.2018.02555 PMID: 30455700
  49. Díaz, L.I.M.; De Pablos, L.M.; Longhi, S.A.; Zago, M.P.; Schijman, A.G.; Osuna, A. Immune complexes in chronic Chagas disease patients are formed by exovesicles from Trypanosoma cruzi carrying the conserved MASP N-terminal region. Sci. Rep., 2017, 7(1), 44451. doi: 10.1038/srep44451 PMID: 28294160
  50. das Dores Pereira, R.; Rabelo, R.A.N.; Leite, P.G.; Cramer, A.; Botelho, A.F.M.; Cruz, J.S.; Régis, W.C.B.; Perretti, M.; Teixeira, M.M.; Machado, F.S. Role of formyl peptide receptor 2 (FPR2) in modulating immune response and heart inflammation in an experimental model of acute and chronic Chagas disease. Cell. Immunol., 2021, 369, 104427. doi: 10.1016/j.cellimm.2021.104427
  51. Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017, 66(4), 683-691. doi: 10.1136/gutjnl-2015-310912 PMID: 26818619
  52. Kopetz, S.; Chang, G.J.; Overman, M.J.; Eng, C.; Sargent, D.J.; Larson, D.W.; Grothey, A.; Vauthey, J.N.; Nagorney, D.M.; McWilliams, R.R. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol., 2009, 27(22), 3677-3683. doi: 10.1200/JCO.2008.20.5278 PMID: 19470929
  53. Sokolova, O.; Naumann, M. Crosstalk between DNA damage and inflammation in the multiple steps of gastric carcinogenesis. Curr. Top. Microbiol. Immunol., 2019, 421, 107-137.
  54. Ruan, H.; Leibowitz, B.J.; Zhang, L.; Yu, J. Immunogenic cell death in colon cancer prevention and therapy. Mol. Carcinog., 2020, 59(7), 783-793. doi: 10.1002/mc.23183 PMID: 32215970
  55. Paskeh, M.D.A.; Entezari, M.; Mirzaei, S.; Zabolian, A.; Saleki, H.; Naghdi, M.J.; Sabet, S.; Khoshbakht, M.A.; Hashemi, M.; Hushmandi, K.; Sethi, G.; Zarrabi, A.; Kumar, A.P.; Tan, S.C.; Papadakis, M.; Alexiou, A.; Islam, M.A.; Mostafavi, E.; Ashrafizadeh, M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J. Hematol. Oncol., 2022, 15(1), 83. doi: 10.1186/s13045-022-01305-4 PMID: 35765040
  56. Galli, F.; Aguilera, J.V.; Palermo, B.; Markovic, S.N.; Nisticò, P.; Signore, A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J. Exp. Clin. Cancer Res., 2020, 39(1), 89. doi: 10.1186/s13046-020-01586-y PMID: 32423420
  57. Corn, K.C.; Windham, M.A.; Rafat, M. Lipids in the tumor microenvironment: From cancer progression to treatment. Prog. Lipid Res., 2020, 80, 101055. doi: 10.1016/j.plipres.2020.101055 PMID: 32791170
  58. Elia, I.; Haigis, M.C. Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism. Nat. Metab., 2021, 3(1), 21-32. doi: 10.1038/s42255-020-00317-z PMID: 33398194
  59. Chan, T.A.; Yarchoan, M.; Jaffee, E.; Swanton, C.; Quezada, S.A.; Stenzinger, A.; Peters, S. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann. Oncol., 2019, 30(1), 44-56. doi: 10.1093/annonc/mdy495 PMID: 30395155
  60. Barrueto, L.; Caminero, F.; Cash, L.; Makris, C.; Lamichhane, P.; Deshmukh, R.R. Resistance to checkpoint inhibition in cancer immunotherapy. Transl. Oncol., 2020, 13(3), 100738. doi: 10.1016/j.tranon.2019.12.010 PMID: 32114384
  61. Li, W.H.; Li, Y.M. Chemical strategies to boost cancer vaccines. Chem. Rev., 2020, 120(20), 11420-11478. doi: 10.1021/acs.chemrev.9b00833 PMID: 32914967
  62. Jiang, M.; Chen, W.; Yu, W.; Xu, Z.; Liu, X.; Jia, Q.; Guan, X.; Zhang, W. Sequentially pH-responsive drug-delivery nanosystem for tumor immunogenic cell death and cooperating with immune checkpoint blockade for efficient cancer chemoimmunotherapy. ACS Appl. Mater. Interfaces, 2021, 13(37), 43963-43974. doi: 10.1021/acsami.1c10643 PMID: 34506118
  63. Osinaga, E. Expression of cancer-associated simple mucin-type O-glycosylated antigens in parasites. IUBMB Life, 2007, 59(4), 269-273. doi: 10.1080/15216540601188553 PMID: 17505964
  64. Bolhassani, A.; Zahedifard, F. Therapeutic live vaccines as a potential anticancer strategy. Int. J. Cancer, 2012, 131(8), 1733-1743. doi: 10.1002/ijc.27640 PMID: 22610886
  65. Junqueira, C.; Caetano, B.; Bartholomeu, D.C.; Melo, M.B.; Ropert, C.; Rodrigues, M.M.; Gazzinelli, R.T. The endless race between Trypanosoma cruzi and host immunity: Lessons for and beyond Chagas disease. Expert Rev. Mol. Med., 2010, 12, e29. doi: 10.1017/S1462399410001560 PMID: 20840799
  66. Wolska, K.; Gorska, A.; Antosik, K.; Lugowska, K. Immunomodulatory effects of propolis and its components on basic immune cell functions. Indian J. Pharm. Sci., 2019, 81(4), 575-588.
  67. Campo, V.L.; Riul, T.B.; Carvalho, I.; Baruffi, M.D. Antibodies against mucin-based glycopeptides affect Trypanosoma cruzi cell invasion and tumor cell viability. ChemBioChem, 2014, 15(10), 1495-1507. doi: 10.1002/cbic.201400069 PMID: 24920542
  68. Yedjou, C.G.; Sims, J.N.; Miele, L.; Noubissi, F.; Lowe, L.; Fonseca, D.D.; Alo, R.A.; Payton, M.; Tchounwou, P.B. Health and racial disparity in breast cancer. Adv. Exp. Med. Biol., 2019, 1152, 31-49. doi: 10.1007/978-3-030-20301-6_3 PMID: 31456178
  69. Yang, R.; Li, Y.; Wang, H.; Qin, T.; Yin, X.; Ma, X. Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol. Biomed., 2022, 3(1), 8. doi: 10.1186/s43556-022-00071-6 PMID: 35243562
  70. Kuroda, H.; Jamiyan, T.; Yamaguchi, R.; Kakumoto, A.; Abe, A.; Harada, O.; Masunaga, A. Tumor microenvironment in triple-negative breast cancer: The correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clin. Transl. Oncol., 2021, 23(12), 2513-2525. doi: 10.1007/s12094-021-02652-3 PMID: 34089486
  71. Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res., 2020, 22(1), 61. doi: 10.1186/s13058-020-01296-5 PMID: 32517735
  72. Lau, K.H.; Tan, A.M.; Shi, Y. New and emerging targeted therapies for advanced breast cancer. Int. J. Mol. Sci., 2022, 23(4), 2288. doi: 10.3390/ijms23042288 PMID: 35216405
  73. Azevedo, S.A.C.; Cristina de Oliveira, R.; Rodrigues, C.C.; Teixeira, S.C.; Borges, B.C.; Vieira da Silva, C. Trypanosoma cruzi infection induces proliferation and impairs migration of a human breast cancer cell line. Exp. Parasitol., 2023, 245, 108443. doi: 10.1016/j.exppara.2022.108443 PMID: 36526003
  74. Crouse, J.; Xu, H.C.; Lang, P.A.; Oxenius, A. NK cells regulating T cell responses: Mechanisms and outcome. Trends Immunol., 2015, 36(1), 49-58. doi: 10.1016/j.it.2014.11.001 PMID: 25432489
  75. Jiang, W.; Xu, J. Immune modulation by mesenchymal stem cells. Cell Prolif., 2020, 53(1), e12712. doi: 10.1111/cpr.12712 PMID: 31730279
  76. Burke, J.D.; Young, H.A. IFN-γ: A cytokine at the right time, is in the right place. Semin. Immunol., 2019, 43, 101280. doi: 10.1016/j.smim.2019.05.002 PMID: 31221552
  77. Jorgovanovic, D.; Song, M.; Wang, L.; Zhang, Y. Roles of IFN-γ: in tumor progression and regression: A review. Biomark. Res., 2020, 8(1), 49. doi: 10.1186/s40364-020-00228-x PMID: 33005420
  78. Lin, Y.; Qi, X.; Liu, H.; Xue, K.; Xu, S.; Tian, Z. The anti-cancer effects of fucoidan: A review of both in vivo and in vitro investigations. Cancer Cell Int., 2020, 20(1), 154. doi: 10.1186/s12935-020-01233-8 PMID: 32410882
  79. Afolabi, L.O.; Bi, J.; Chen, L.; Wan, X. A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. Int. Immunopharmacol., 2021, 96, 107658. doi: 10.1016/j.intimp.2021.107658 PMID: 33887610
  80. Ehteshamfar, S.M.; Akhbari, M.; Afshari, J.T.; Seyedi, M.; Nikfar, B.; Shapouri-Moghaddam, A.; Ghanbarzadeh, E.; Momtazi-Borojeni, A.A. Anti‐inflammatory and immune‐modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J. Cell. Mol. Med., 2020, 24(23), 13573-13588. doi: 10.1111/jcmm.16049 PMID: 33135395
  81. Ullrich, K.A.M.; Schulze, L.L.; Paap, E.M.; Müller, T.M.; Neurath, M.F.; Zundler, S. Immunology of IL-12: An update on functional activities and implications for disease. EXCLI J., 2020, 19, 1563-1589. PMID: 33408595
  82. Huang, C.; Bi, J. Expression regulation and function of T-Bet in NK cells. Front. Immunol., 2021, 12, 761920. doi: 10.3389/fimmu.2021.761920 PMID: 34675939
  83. Brevi, A.; Cogrossi, L.L.; Grazia, G.; Masciovecchio, D.; Impellizzieri, D.; Lacanfora, L.; Grioni, M.; Bellone, M. Much more than IL-17A: cytokines of the IL-17 family between microbiota and cancer. Front. Immunol., 2020, 11, 565470. doi: 10.3389/fimmu.2020.565470 PMID: 33244315
  84. Ruiz de Morales, J.M.G.; Puig, L.; Daudén, E.; Cañete, J.D.; Pablos, J.L.; Martín, A.O.; Juanatey, C.G.; Adán, A.; Montalbán, X.; Borruel, N.; Ortí, G.; Holgado-Martín, E.; García-Vidal, C.; Vizcaya-Morales, C.; Martín-Vázquez, V.; González-Gay, M.Á. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun. Rev., 2020, 19(1), 102429. doi: 10.1016/j.autrev.2019.102429 PMID: 31734402
  85. Amezcua Vesely, M.C.; Rodríguez, C.; Gruppi, A.; Acosta, R.E.V. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans. Biochim. Biophys. Acta Mol. Basis Dis., 2020, 1866(5), 165706. doi: 10.1016/j.bbadis.2020.165706 PMID: 31987839
  86. Chung, S.H.; Ye, X.Q.; Iwakura, Y. Interleukin-17 family members in health and disease. Int. Immunol., 2021, 33(12), 723-729. doi: 10.1093/intimm/dxab075 PMID: 34611705
  87. Wu, S.Y.; Fu, T.; Jiang, Y.Z.; Shao, Z.M. Natural killer cells in cancer biology and therapy. Mol. Cancer, 2020, 19(1), 120. doi: 10.1186/s12943-020-01238-x PMID: 32762681
  88. Farhood, B.; Najafi, M.; Mortezaee, K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol., 2019, 234(6), 8509-8521. doi: 10.1002/jcp.27782 PMID: 30520029
  89. Huntington, N.D.; Cursons, J.; Rautela, J. The cancer-natural killer cell immunity cycle. Nat. Rev. Cancer, 2020, 20(8), 437-454. doi: 10.1038/s41568-020-0272-z PMID: 32581320
  90. Tay, R.E.; Richardson, E.K.; Toh, H.C. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. Cancer Gene Ther., 2021, 28(1-2), 5-17. doi: 10.1038/s41417-020-0183-x PMID: 32457487
  91. Patel, C.H.; Leone, R.D.; Horton, M.R.; Powell, J.D. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat. Rev. Drug Discov., 2019, 18(9), 669-688. doi: 10.1038/s41573-019-0032-5 PMID: 31363227
  92. Schuijs, M.J.; Hammad, H.; Lambrecht, B.N. Professional and 'amateur'antigen-presenting cells in type 2 immunity. Trends Immunol., 2019, 40(1), 22-34. doi: 10.1016/j.it.2018.11.001 PMID: 30502024
  93. Zhu, X.; Zhu, J. CD4 T helper cell subsets and related human immunological disorders. Int. J. Mol. Sci., 2020, 21(21), 8011. doi: 10.3390/ijms21218011 PMID: 33126494
  94. Richardson, J.R.; Schöllhorn, A.; Gouttefangeas, C.; Schuhmacher, J. CD4+ T cells: Multitasking cells in the duty of cancer immunotherapy. Cancers, 2021, 13(4), 596. doi: 10.3390/cancers13040596 PMID: 33546283
  95. Lo Nigro, C.; Macagno, M.; Sangiolo, D.; Bertolaccini, L.; Aglietta, M.; Merlano, M.C. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives. Ann. Transl. Med., 2019, 7(5), 105. doi: 10.21037/atm.2019.01.42 PMID: 31019955
  96. Roumenina, L.T.; Daugan, M.V.; Petitprez, F.; Sautès-Fridman, C.; Fridman, W.H. Context-dependent roles of complement in cancer. Nat. Rev. Cancer, 2019, 19(12), 698-715. doi: 10.1038/s41568-019-0210-0 PMID: 31666715
  97. Ramírez-Toloza, G.; Aguilar-Guzmán, L.; Valck, C.; Ferreira, V.P.; Ferreira, A. The interactions of parasite calreticulin with initial complement components: Consequences in immunity and virulence. Front. Immunol., 2020, 11, 1561. doi: 10.3389/fimmu.2020.01561 PMID: 32793217
  98. Sosoniuk-Roche, E.; Cruz, P.; Maldonado, I.; Duaso, L.; Pesce, B.; Michalak, M.; Valck, C.; Ferreira, A. In vitro treatment of a murine mammary adenocarcinoma cell line with recombinant Trypanosoma cruzi calreticulin promotes immunogenicity and phagocytosis. Mol. Immunol., 2020, 124, 51-60. doi: 10.1016/j.molimm.2020.05.013 PMID: 32526557
  99. Huang, Y.; Hui, K.; Jin, M.; Yin, S.; Wang, W.; Ren, Q. Two endoplasmic reticulum proteins (calnexin and calreticulin) are involved in innate immunity in Chinese mitten crab (Eriocheir sinensis). Sci. Rep., 2016, 6(1), 27578. doi: 10.1038/srep27578 PMID: 27279413
  100. Wang, W.A.; Groenendyk, J.; Michalak, M. Calreticulin signaling in health and disease. Int. J. Biochem. Cell Biol., 2012, 44(6), 842-846. doi: 10.1016/j.biocel.2012.02.009 PMID: 22373697
  101. Wiseman, R.L.; Mesgarzadeh, J.S.; Hendershot, L.M. Reshaping endoplasmic reticulum quality control through the unfolded protein response. Mol. Cell, 2022, 82(8), 1477-1491. doi: 10.1016/j.molcel.2022.03.025 PMID: 35452616
  102. Kielbik, M.; Szulc-Kielbik, I.; Klink, M. Calreticulin—Multifunctional chaperone in immunogenic cell death: Potential significance as a prognostic biomarker in ovarian cancer patients. Cells, 2021, 10(1), 130. doi: 10.3390/cells10010130 PMID: 33440842
  103. Pandya, U.M.; Manzanares, M.A.; Tellechea, A.; Egbuta, C.; Daubriac, J.; Jimenez-Jaramillo, C.; Samra, F.; Fredston-Hermann, A.; Saadipour, K.; Gold, L.I. Calreticulin exploits TGF‐β for extracellular matrix induction engineering a tissue regenerative process. FASEB J., 2020, 34(12), 15849-15874. doi: 10.1096/fj.202001161R PMID: 33015849
  104. Kotian, V.; Sarmah, D.; Kaur, H.; Kesharwani, R.; Verma, G.; Mounica, L.; Veeresh, P.; Kalia, K.; Borah, A.; Wang, X.; Dave, K.R.; Yavagal, D.R.; Bhattacharya, P. Evolving evidence of calreticulin as a pharmacological target in neurological disorders. ACS Chem. Neurosci., 2019, 10(6), 2629-2646. doi: 10.1021/acschemneuro.9b00158 PMID: 31017385
  105. Schcolnik-Cabrera, A.; Oldak, B.; Juárez, M.; Cruz-Rivera, M.; Flisser, A.; Mendlovic, F. Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes. Apoptosis, 2019, 24(3-4), 245-255. doi: 10.1007/s10495-019-01532-0 PMID: 30929105
  106. Labriola, C.A.; Giraldo, A.M.V.; Parodi, A.J.; Caramelo, J.J. Functional cooperation between BiP and calreticulin in the folding maturation of a glycoprotein in Trypanosoma cruzi. Mol. Biochem. Parasitol., 2011, 175(2), 112-117. doi: 10.1016/j.molbiopara.2010.10.002 PMID: 20934456
  107. Labriola, C.A.; Conte, I.L.; López Medus, M.; Parodi, A.J.; Caramelo, J.J. Endoplasmic reticulum calcium regulates the retrotranslocation of Trypanosoma cruzi calreticulin to the cytosol. PLoS One, 2010, 5(10), e13141. doi: 10.1371/journal.pone.0013141 PMID: 20957192
  108. Ramírez, G.; Valck, C.; Ferreira, V.P.; López, N.; Ferreira, A. Extracellular Trypanosoma cruzi calreticulin in the host–parasite interplay. Trends Parasitol., 2011, 27(3), 115-122. doi: 10.1016/j.pt.2010.12.007 PMID: 21288773
  109. Reyes, A.C.; Encina, J.L.R. Trypanosoma cruzi infection: Mechanisms of evasion of immune response. Biol. Trypanosoma. cruzi., 2019, 11, 153-173.
  110. Ramírez-Toloza, G.; Abello, P.; Ferreira, A. Is the antitumor property of Trypanosoma cruzi infection mediated by its calreticulin? Front. Immunol., 2016, 7, 268. doi: 10.3389/fimmu.2016.00268 PMID: 27462315
  111. Ramírez, G.; Valck, C.; Aguilar, L.; Kemmerling, U.; López-Muñoz, R.; Cabrera, G.; Morello, A.; Ferreira, J.; Maya, J.D.; Galanti, N.; Ferreira, A. Roles of Trypanosoma cruzi calreticulin in parasite–host interactions and in tumor growth. Mol. Immunol., 2012, 52(3-4), 133-140. doi: 10.1016/j.molimm.2012.05.006 PMID: 22673211
  112. Ferreira, V.; Valck, C.; Sánchez, G.; Gingras, A.; Tzima, S.; Molina, M.C.; Sim, R.; Schwaeble, W.; Ferreira, A. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol., 2004, 172(5), 3042-3050. doi: 10.4049/jimmunol.172.5.3042 PMID: 14978109
  113. Venkateswaran, K.; Verma, A.; Bhatt, A.N.; Shrivastava, A.; Manda, K.; Raj, H.G.; Prasad, A.; Len, C.; Parmar, V.S.; Dwarakanath, B.S. Emerging roles of calreticulin in cancer: Implications for therapy. Curr. Protein Pept. Sci., 2018, 19(4), 344-357. doi: 10.2174/1389203718666170111123253 PMID: 28079009
  114. Sánchez, D.; Palová-Jelínková, L.; Felsberg, J.; Šimšová, M.; Pekáriková, A.; Pecharová, B.; Swoboda, I.; Mothes, T.; Mulder, C.J.J.; Beneš, Z.; Tlaskalová-Hogenová, H. Tučková, L. Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease. Clin. Exp. Immunol., 2008, 153(3), 351-359. doi: 10.1111/j.1365-2249.2008.03701.x PMID: 18637103
  115. Abello-Cáceres, P.; Pizarro-Bauerle, J.; Rosas, C.; Maldonado, I.; Aguilar-Guzmán, L.; González, C.; Ramírez, G.; Ferreira, J.; Ferreira, A. Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection? BMC Cancer, 2016, 16(1), 731. doi: 10.1186/s12885-016-2764-5 PMID: 27619675
  116. Ramírez-Toloza, G.; Ferreira, A. Trypanosoma cruzi evades the complement system as an efficient strategy to survive in the mammalian host: The specific roles of host/parasite molecules and Trypanosoma cruzi calreticulin. Front. Microbiol., 2017, 8, 1667. doi: 10.3389/fmicb.2017.01667 PMID: 28919885
  117. López, N.C.; Valck, C.; Ramírez, G.; Rodríguez, M.; Ribeiro, C.; Orellana, J.; Maldonado, I.; Albini, A.; Anacona, D.; Lemus, D.; Aguilar, L.; Schwaeble, W.; Ferreira, A. Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin. PLoS Negl. Trop. Dis., 2010, 4(7), e730. doi: 10.1371/journal.pntd.0000730 PMID: 20625551
  118. Ramírez-Toloza, G.; Aguilar-Guzmán, L.; Valck, C.; Abello, P.; Ferreira, A. Is it all that bad when living with an intracellular protozoan? The role of Trypanosoma cruzi calreticulin in angiogenesis and tumor growth. Front. Oncol., 2015, 4, 382. doi: 10.3389/fonc.2014.00382 PMID: 25629005
  119. Borges, B.C.; Uehara, I.A.; Dias, L.O.S.; Brígido, P.C.; da Silva, C.V.; Silva, M.J.B. Mechanisms of infectivity and evasion derived from microvesicles cargo produced by Trypanosoma cruzi. Front. Cell. Infect. Microbiol., 2016, 6, 161. doi: 10.3389/fcimb.2016.00161 PMID: 27921011
  120. Ferri, G.; Edreira, M.M. All roads lead to cytosol: Trypanosoma cruzi multi-strategic approach to invasion. Front. Cell. Infect. Microbiol., 2021, 11, 634793. doi: 10.3389/fcimb.2021.634793 PMID: 33747982
  121. Umarao, P.; Rath, P.P.; Gourinath, S. Cdc42/Rac Interactive binding containing effector proteins in unicellular protozoans with reference to human host: Locks of the Rho signaling. Front. Genet., 2022, 13, 781885. doi: 10.3389/fgene.2022.781885 PMID: 35186026
  122. Martins, F.A.; dos Santos, M.A.; Santos, J.G.; da Silva, A.A.; Borges, B.C.; da Costa, M.S.; Tavares, P.C.B.; Teixeira, S.C.; Brígido, R.T.S.; Teixeira, T.L.; Rodrigues, C.C.; Silva, N.S.L.; de Oliveira, R.C.; de Faria, L.C.; Lemes, M.R.; Zanon, R.G.; Tomiosso, T.C.; Machado, J.R.; da Silva, M.V.; Oliveira, C.J.F.; da Silva, C.V. The recombinant form of Trypanosoma cruzi P21 controls infection by modulating host immune response. Front. Immunol., 2020, 11, 1010. doi: 10.3389/fimmu.2020.01010 PMID: 32655546
  123. Barbosa, J.S.; Moura, F.B.R.; Ferreira, B.A.; Martins, F.A.; Muniz, E.H.; Gomide, J.A.L.; Silva, C.V.; Ribeiro, D.L.; Araújo, F.A.; Tomiosso, T.C. Recombinant protein rP21 from Trypanosoma cruzi has effect on inflammation, angiogenesis and fibrogenesis in skin wound model C57BL/6 Mouse. Adv. Res., 2021, 22, 28-37. doi: 10.9734/air/2021/v22i130285
  124. Khare, T.; Bissonnette, M.; Khare, S. CXCL12-CXCR4/CXCR7 axis in colorectal cancer: Therapeutic target in preclinical and clinical studies. Int. J. Mol. Sci., 2021, 22(14), 7371. doi: 10.3390/ijms22147371 PMID: 34298991
  125. Shi, Y.; Riese, D.J., II; Shen, J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front. Pharmacol., 2020, 11, 574667. doi: 10.3389/fphar.2020.574667 PMID: 33363463
  126. Bianchi, M.E.; Mezzapelle, R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front. Immunol., 2020, 11, 2109. doi: 10.3389/fimmu.2020.02109 PMID: 32983169
  127. Daniel, S.K.; Seo, Y.D.; Pillarisetty, V.G. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin. Cancer Biol., 2020, 65, 176-188. doi: 10.1016/j.semcancer.2019.12.007 PMID: 31874281
  128. Cohen-Solal, K.A.; Boregowda, R.K.; Lasfar, A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol. Cancer, 2015, 14(1), 137. doi: 10.1186/s12943-015-0404-3 PMID: 26204939
  129. Teixeira, S.C.; Lopes, D.S.; Gimenes, S.N.C.; Teixeira, T.L.; da Silva, M.S.; Brígido, R.T.S.; da Luz, F.A.C.; da Silva, A.A.; Silva, M.A.; Florentino, P.V.; Tavares, P.C.B.; dos Santos, M.A.; Ávila, V.M.R.; Silva, M.J.B.; Elias, M.C.; Mortara, R.A.; da Silva, C.V. Mechanistic insights into the anti-angiogenic activity of Trypanosoma cruzi protein 21 and its potential impact on the onset of chagasic cardiomyopathy. Sci. Rep., 2017, 7(1), 44978. doi: 10.1038/srep44978 PMID: 28322302
  130. Teixeira, T.L.; Castilhos, P.; Rodrigues, C.C.; da Silva, A.A.; Brígido, R.T.S.; Teixeira, S.C.; Borges, B.C.; Dos Santos, M.A.; Martins, F.A.; Santos, P.C.F.; Servato, J.P.S.; Silva, M.S.; da Silva, M.J.B.; Elias, M.C.; da Silva, C.V. Experimental evidences that P21 protein controls Trypanosoma cruzi replication and modulates the pathogenesis of infection. Microb. Pathog., 2019, 135, 103618. doi: 10.1016/j.micpath.2019.103618 PMID: 31310832
  131. Teixeira, T.L.; Machado, F.C.; Alves da Silva, A.; Teixeira, S.C.; Borges, B.C.; dos Santos, M.A.; Martins, F.A.; Brígido, P.C.; Rodrigues, A.A.; Notário, A.F.O.; Ferreira, B.A.; Servato, J.P.S.; Deconte, S.R.; Lopes, D.S.; Ávila, V.M.R.; Araújo, F.A.; Tomiosso, T.C.; Silva, M.J.B.; da Silva, C.V. Trypanosoma cruzi P21: A potential novel target for chagasic cardiomyopathy therapy. Sci. Rep., 2015, 5(1), 16877. doi: 10.1038/srep16877 PMID: 26574156
  132. Wu, A.A.; Drake, V.; Huang, H.S.; Chiu, S.; Zheng, L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology, 2015, 4(7), e1016700. doi: 10.1080/2162402X.2015.1016700 PMID: 26140242
  133. Groux-Degroote, S.; Cavdarli, S.; Uchimura, K.; Allain, F.; Delannoy, P. Glycosylation changes in inflammatory diseases. Adv. Protein Chem. Struct. Biol., 2020, 119, 111-156. doi: 10.1016/bs.apcsb.2019.08.008 PMID: 31997767
  134. Peixoto, A.; Relvas-Santos, M.; Azevedo, R.; Santos, L.L.; Ferreira, J.A. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front. Oncol., 2019, 9, 380. doi: 10.3389/fonc.2019.00380 PMID: 31157165
  135. Kasprzak, A.; Adamek, A. Mucins: The old, the new and the promising factors in hepatobiliary carcinogenesis. Int. J. Mol. Sci., 2019, 20(6), 1288. doi: 10.3390/ijms20061288 PMID: 30875782
  136. Berois, N.; Pittini, A.; Osinaga, E. Targeting tumor glycans for cancer therapy: Successes, limitations, and perspectives. Cancers, 2022, 14(3), 645. doi: 10.3390/cancers14030645 PMID: 35158915
  137. Jin, K.T.; Lan, H.R.; Chen, X.Y.; Wang, S.B.; Ying, X.J.; Lin, Y.; Mou, X.Z. Recent advances in carbohydrate-based cancer vaccines. Biotechnol. Lett., 2019, 41(6-7), 641-650. doi: 10.1007/s10529-019-02675-5 PMID: 30993481
  138. Mantovani, A.; Romero, P.; Palucka, A.K.; Marincola, F.M. Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet, 2008, 371(9614), 771-783. doi: 10.1016/S0140-6736(08)60241-X PMID: 18275997
  139. Giorgi, M.E.; Lederkremer, R.M. The glycan structure of T. cruzi mucins depends on the host. Insights on the chameleonic galactose. Molecules, 2020, 25(17), 3913. doi: 10.3390/molecules25173913 PMID: 32867240
  140. Martins-Teixeira, M.B. Campo, V.L.; Biondo, M.; Sesti-Costa, R.; Carneiro, Z.A.; Silva, J.S.; Carvalho, I. α-Selective glycosylation affords mucin-related GalNAc amino acids and diketopiperazines active on Trypanosoma cruzi. Bioorg. Med. Chem., 2013, 21(7), 1978-1987. doi: 10.1016/j.bmc.2013.01.027 PMID: 23415086
  141. Leiria, C. V.; Braga Martins-Teixeira, M.; Carvalho, I. Trypanosoma cruzi invasion into host cells: A complex molecular targets interplay. Mini Rev. Med. Chem., 2016, 16(13), 1084-1097. doi: 10.2174/1389557516666160607230238 PMID: 27281167
  142. Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med., 2014, 20(6), 332-342. doi: 10.1016/j.molmed.2014.02.007 PMID: 24667139
  143. Schirrmacher, V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. Int. J. Oncol., 2018, 54(2), 407-419. doi: 10.3892/ijo.2018.4661 PMID: 30570109
  144. Anwanwan, D.; Singh, S.K.; Singh, S.; Saikam, V.; Singh, R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer, 2020, 1873(1), 188314. doi: 10.1016/j.bbcan.2019.188314 PMID: 31682895
  145. Duan, X.; Chan, C.; Lin, W. Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew. Chem. Int. Ed., 2019, 58(3), 670-680. doi: 10.1002/anie.201804882 PMID: 30016571
  146. Raza, F.; Zafar, H.; Zhang, S.; Kamal, Z.; Su, J.; Yuan, W.E.; Mingfeng, Q. Recent advances in cell membrane‐derived biomimetic nanotechnology for cancer immunotherapy. Adv. Healthc. Mater., 2021, 10(6), 2002081. doi: 10.1002/adhm.202002081 PMID: 33586322
  147. Aikins, M.E.; Xu, C.; Moon, J.J. Engineered nanoparticles for cancer vaccination and immunotherapy. Acc. Chem. Res., 2020, 53(10), 2094-2105. doi: 10.1021/acs.accounts.0c00456 PMID: 33017150
  148. Zaheer, T.; Pal, K.; Zaheer, I. Topical review on nano-vaccinology: Biochemical promises and key challenges. Process Biochem., 2021, 100, 237-244. doi: 10.1016/j.procbio.2020.09.028 PMID: 33013180
  149. Zhao, Y.; Baldin, A.V.; Isayev, O.; Werner, J.; Zamyatnin, A.A., Jr; Bazhin, A.V. Cancer vaccines: Antigen selection strategy. Vaccines, 2021, 9(2), 85. doi: 10.3390/vaccines9020085 PMID: 33503926
  150. Lantier, L.; Poupée-Beaugé, A.; di Tommaso, A.; Ducournau, C.; Epardaud, M.; Lakhrif, Z.; Germon, S.; Debierre-Grockiego, F.; Mévélec, M.N.; Battistoni, A.; Coënon, L.; Deluce-Kakwata-Nkor, N.; Velge-Roussel, F.; Beauvillain, C.; Baranek, T.; Lee, G.S.; Kervarrec, T.; Touzé, A.; Moiré, N.; Dimier-Poisson, I. Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer. J. Immunother. Cancer, 2020, 8(2), e001242. doi: 10.1136/jitc-2020-001242 PMID: 33257408
  151. Pereira, I.R.; Vilar-Pereira, G.; Marques, V.; da Silva, A.A.; Caetano, B.; Moreira, O.C.; Machado, A.V.; Bruna-Romero, O.; Rodrigues, M.M.; Gazzinelli, R.T.; Lannes-Vieira, J. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog., 2015, 11(1), e1004594. doi: 10.1371/journal.ppat.1004594 PMID: 25617628
  152. Aguilar-Guzmán, L.; Lobos-González, L.; Rosas, C.; Vallejos, G.; Falcón, C.; Sosoniuk, E.; Coddou, F.; Leyton, L.; Lemus, D.; Quest, A.F.G.; Ferreira, A. Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One, 2014, 9(4), e95457. doi: 10.1371/journal.pone.0095457 PMID: 24755644

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bentham Science Publishers